Skip to main content
SpringerLink
Log in

Hypertension in the elderly

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Both systolic and diastolic blood pressure increase with advanced ageand more than 50% of hypertensive patients are aged above 65years. Age-related vascular and neuro-humoral changes are importantfactors leading to the development of hypertension in the elderly andthe increase in systolic and diastolic blood pressure with age in anyindividual is a consequence of the relative change in arterialresistance and stiffness. Therefore, hypertension is predominantly orpurely systolic in the elderly both in women and men. The risks ofhypertensive patients over the age of 65 years are significant andseveral trials have provided compelling evidence that treatment ofhypertension in the elderly is beneficial in terms of reduced morbidityand mortality. Goal blood pressure should be similar in older andyounger patients. Lifestyle modifications are of proven benefit and maybe the only therapy needed for stage 1 hypertension. The Sixth report ofthe JNC recommends diuretics, specifically thiazide diuretics as theinitial choice for the treatment of elderly patients without anycomorbid conditions. Beta-blockers are less effective than thiazides asfirst line treatment and may only reduce stroke events. Recently,dihydropiridine calcium antagonists have been advocated as first choiceagents for the treatment of hypertension in the elderly and are suitablealternatives when diuretics are ineffective, contraindicated or nottolerated. Newer drugs such as AT1 antagonists are also effective inlowering blood pressure in the elderly but large scale data concerningtheir protective effects are still lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Messerli FH. Essencial hypertension in the elderly. Triangle 1985; 24: 35–47

    Google Scholar 

  2. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hyper-tension in the US adult population. Results from the Third National Health and Nutrition Examination Survey 1988–91. Hypertension 1995; 25: 305–313

    Google Scholar 

  3. Grassi G, Seravalle G, Bertinieri G et al. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens 2000; 18: 587–593

    Google Scholar 

  4. Safar ME, Rudnichi A, Asmar R. Drug treatment of hyper-tension: the reduction of pulse pressure does not necessarily parallel that of systolic and diastolic blood pressure. J Hyper-tens 2000; 18: 1159–1163

    Google Scholar 

  5. Safar ME, Blacher J, Mourad JJ et al. Stiffness of carotid artery wall material and blood pressure in humans. Stroke 2000; 31: 782–790

    Google Scholar 

  6. Messerli FH, Ventura HO, Glade LB et al. Essential hyper-tension in the elderly: haemodinamics, intravascular volume, plasma rennin activity, and circulating catecholamine levels. Lancet 1983; 2: 983–986

    Google Scholar 

  7. van Zwieten PA. Drug treatment of isolated systolic hyperten-sion. Nephrol Dial Transplant 2001; 16: 1095–1097

    Google Scholar 

  8. Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the Systolic Hypertension in the Elderly Program. Hypertension 1993; 21: 335–343

    Google Scholar 

  9. Kannel WB, Wolf PA, McGee DL et al. Systolic blood pres-sure, arterial rigidity and risk of stroke: The Framingham Study. J Am Med Assoc 1981; 45: 1225–1229

    Google Scholar 

  10. Kannel WB, Gordon T. Evaluation of cardiovascular risk in the elderly: The Framingham Study. Bull NY Acad Med 1978; 54: 573–591

    Google Scholar 

  11. MacMahon S, Rodgers A. The effects of blood pressure reduc-tion in older patients. An overview of five controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967–978

    Google Scholar 

  12. Ostfeld AM. Elderly hypertensive patient. NY State J Med 1978; 78: 1125

    Google Scholar 

  13. Kannel WB, Castelli WP, McNamara PM et al. Role of blood pressure in the development of congestive failure: The Framingham Study. N Engl J Med 1972; 287: 781–787

    Google Scholar 

  14. Hypertension Detection and Follow-up Program. Detection and treatment of hypertension in older individuals. Am J Epidemiol 1985; 121: 371–376

    Google Scholar 

  15. Neaton JD, Wentworth D. Serum cholesterol, blood pres-sure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Int Med 1992; 152: 56–64

    Google Scholar 

  16. Veterans Administration Co-operative Study on Antihyper-tensive Agents. Effects of treatment on morbidity in hyper-tension. III: Influence of age, diastolic pressure and prior cardiovascular disease. Circulation 1972; 45: 991–1004

    Google Scholar 

  17. Amery A, Birkenhager W, Brixko P et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; 2: 1349–1354

    Google Scholar 

  18. Dahlof B, Lindholm L, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hyperten-sion (STOP-Hypertension). Lancet 1991; 338: 1281–1285

    Google Scholar 

  19. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hyperten-sion Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762

    Google Scholar 

  20. Messerli FH, Grossman E, Goldbourt U. Are â-blockers effic-acious as first line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903–1907

    Google Scholar 

  21. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–3264

    Google Scholar 

  22. SYST-EUR Trial Investigators. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764

    Google Scholar 

  23. Forette F, Seux ML, Staessen JA. Prevention of dementia in randomised double blind placebo-controlled systolic hyper-tension in Europe (SYST-EUR) trial. Lancet 1998; 352: 1347–1351

    Google Scholar 

  24. Liu J, Wang GJ, Gong L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (SYST-China) collaborative study. J Hypertens 1998; 16: 1823–1829

    Google Scholar 

  25. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine-GITS Study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366–372

    Google Scholar 

  26. Brown MJ, Castaigne A, de Leeuw PW et al. Influence of diabetes and type of hypertension on response to antihyper-tensive treatment. Hypertension 2000; 35: 1038–1042

    Google Scholar 

  27. Staessen JA, Gasowski J, Wang JL et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872

    Google Scholar 

  28. Kaplan NM. Treatment of hypertension: Rationale, guidelines, and goals. In: Kaplan NM, ed. Clinical Hypertension 7th ed. Baltimore, Williams and Wilkins 1998, pp. 133–158

    Google Scholar 

  29. Geleijnse JM, Witteman JCM, Bak AAA et al. Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. Br Med J 1994; 309: 436–440

    Google Scholar 

  30. Joint National Committee on Prevention, Detaction, Evalu-ation and Treatment of High Blood Pressure. The Six Report. Arch Intern Med 1997; 157: 2413–2446

    Google Scholar 

  31. Krumholz HM, Radford MJ, Wang et al. for the National Cooperative Cardiovascular Project. National use and effect-iveness of â-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA 1998; 280: 623–629

    Google Scholar 

  32. Burns B, Frishman W. Calcium antagonists in elderly patients with systemic hypertension. In Calcium Antagonists in Clin-ical Medicine 2nd ed. In: Epstein M, ed. Hanley & Belfus, Philadelphia 1998, pp. 307–320

    Google Scholar 

  33. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342(13): 905–912

    Google Scholar 

  34. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet 1999; 353(9153): 611–616

    Google Scholar 

  35. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–153

    Google Scholar 

  36. Farsang C, Garcia-Puig J, Niegowska J et al. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension.J Hypertens 2000; 18: 795–802

    Google Scholar 

  37. Larochelle P, Smith DHG, Ouellet J et al. Efficacy and safety of omapatrilate in subjects with isolated systolic hypertension. Vasopeptidase Inhibition 2000; 2: 110–111

    Google Scholar 

  38. Lim PO, Jung RT, MacDonald TMM. Raised aldosterone to rennin ratio predicts antihypertensive efficacy of spiro-nolacone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999; 48: 756–760

    Google Scholar 

  39. Safar ME. Antihypertensive effects of nitrates in chronic human hypertension. J Appl Cardiol 1990; 5: 69–81

    Google Scholar 

  40. Guidelines Subcommittee. 1999 World Health Organization – International Society of Hypertension Guidelined for the management of hypertension. J Hypertens 1999; 17: 151–183

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculdade de Medicina da UP e Hospital de S. João, Serviço de Nefrologia, 4200, Porto, Portugal

    Manuel Pestana

Authors
  1. Manuel Pestana
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pestana, M. Hypertension in the elderly. Int Urol Nephrol 33, 563–569 (2001). https://doi.org/10.1023/A:1019552602793

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1019552602793

Search

Navigation